Amanda Johnson, MD
@amjohnsonMD
Followers
992
Following
641
Media
59
Statuses
228
Gastroenterologist at @MayoClinicGIHep with clinical and research interests in #IBD and #obesity. Tweets are my own.
Rochester, Minnesota
Joined August 2017
GLP1-Receptor agonists & Clinical Outcomes of IBD: A Syst. Review/Meta-analysis. https://t.co/OA5hEmqb2P 👉11 studies with 16,242 IBD pt Rx with GLP1-RAs 👉wt loss ~various GLP1RAs included 👉GLP1- RAs assoc 🔽risk of surgery 👉Sens. analysis: 🔽risk hosp./surgery in BMI≥30
academic.oup.com
SummaryBackground. Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, su
1
8
31
Patients with Crohn’s Disease and Ileostomy Can Respond to Upadacitinib | Digestive Diseases and Sciences @LaurenLoebMD @ibdgijami @ibdgijami @JHashashMD @FarrayeIBD
link.springer.com
Digestive Diseases and Sciences - Recent studies have established a role for Janus kinase (JAK) inhibitors in the management of patients with inflammatory bowel disease. However, these studies...
1
10
59
Another clinically useful RWE data output from #REBOOTIBD consortium led @amjohnsonMD @MayoClinicGIHep Longer tweet to follow on data! Multicenter Study of the Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease @JCC_IBD @Y_ECCO_IBD
academic.oup.com
AbstractBackground. We aimed to evaluate the effectiveness and safety of risankizumab (RZB) for Crohn’s disease (CD) in routine clinical practice.Methods.
1
7
19
🚨New Study Alert!🚨 🔹 Real-World Effectiveness & Safety of Upa in CD 📖 1st author, 1st paper in @AGA_CGH 🙏 Huge thanks to @P_DeepakIBDMD mentorship & to all collaborators. #AnthonyXu #MollyStone #AnishPatel #AbdulKhan #NikhilReddy 🔗 Read more: https://t.co/063BuAh1we
5
24
85
Interesting paradigm of adding GLP1RAs in patients with #IBD with positive clinical outcomes reported from multiple centers, whether impact on VAT compartment &/or epithelial healing, to be studied in upcoming trial funded @HelmsleyTrust led by #LouisCohen myself & @AndresYarur
🔟🎙️@P_DeepakIBDMD 🧐Why does visceral fat impact IBD? 🔹 Acts as an autocrine organ⏩inflammation 🔹 Alters💊distribution & lymphatic🌊 🔹 Shares⛓️ inflammatory🛣️ w/ IBD ⚖️Can weight loss improve IBD outcomes? ✅ Exercise⬇️ VAT 🥗diet shows promise ✅ GLP-1s & bariatric✂️
0
5
25
Keynote from @AndresYarur on metabolic implications in IBD ⏭️ MASLD is common in IBD, even without usual risk factors ⏭️ Prevalence of obesity in IBD is rising ⏭️ Visceral adiposity may have implications on response to biologic therapy #AIBD24
1
13
39
Biopsy ulcer edge in pyoderma (despite concern for pathergy) to get H&E and tissue culture to rule out infectious causes, including atypical fungal, mycobacterial ❗️Dx and Tx early for best results 🔑 reduce acute inflammation, reduce driver (IBD), heal the wound #AIBD2024
1
5
23
IT IS ALIVE @AmerGastroAssn #UlcerativeColitis @berkeleydoc @ManasiAgrawalMD @JHaydek @AshwinMDIBD @FrankIScottMD
🌟 Our first-ever living guideline for managing moderate-to-severe #UlcerativeColitis led by @berkeleydoc, @manasiagrawalmd, @Jhaydek, @ashwinmdibd, @FrankIScottMD, @EdwardLoftus2 prioritizes early use of advanced therapies over a step-up approach. https://t.co/1Aw21iDSwP
4
6
56
Risankizumab for Ulcerative Colitis https://t.co/hX3rdMZiVy
@JAMA_current @RPanaccione @JeanFredericCo1
jamanetwork.com
These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.
0
28
84
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease #risankizumab
2
24
91
US Insurers Out of Step With IBD Treatment Guidelines https://t.co/y7dFX6E30l
https://t.co/y7dFX6E30l There's no scientific reason to require #IBD patients to fail 5-ASA or thiopurine/methotrexate monotherapy prior to starting an advanced therapy
2
18
56
Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr… https://t.co/BR7fJqZ5hR Nice collaborative work from NYCCO !
pubmed.ncbi.nlm.nih.gov
In this interim analysis of patients with IBD and a history of cancer, despite numerically increased adjusted hazard ratios, we did not find a statistically significant association between subsequent...
0
18
46
Do you want to know real-world effectiveness & safety of Upadacitinib in CD? check @jalpa_devi at #1882. #DDW2024 @WUGastro @amjohnsonMD @P_DeepakIBDMD @MayoClinicGIHep
0
6
17
The positive spin is maybe for our surgical colleagues to routinely follow this protocol to improve surgical results for perianal disease. Still a huge unmet need for our patients. #DDW2024 @AnthonydeBuck @mantaj_brar
Prof Laura Raffals presenting results of the international ADMIRE-CD trial of darvadstrocel (mesnchymal stem cells) in treatment of complex #Crohns perianal fistulas #DDW2024 unfortunately a negative trial, very high “placebo” rate @LauraRaffalsMD @MayoClinicGIHep
2
4
13
The #REBOOTIBD group (minus a few) with our poster on RWE of risankizumab in Crohns @ManarAskar1 @P_DeepakIBDMD @ryanungaro @IBDimmunology @AndresYarur @richashuklaMD @jalpa_devi
0
7
27
So proud of @penngihep & @milestoneibd fellow Priya Sehgal at podium to standing-room-only talk on our work looking at safety & efficacy of GLP-1 agonists in #IBD. Experience same as gen pop; no safety concerns, similar side effects, ⬇️ CRP & effective weight loss.
1
6
26
Intriguing talk from @IBD_FloMD on creeping fat (CF) and CD stricturing ✅CF persists following endoscopic remission, and is immunologically active ✅CF assoc w/ smooth muscle proliferation/stricturing ✅degree CF on CTE correlates with intestinal fibrotic stricturing
1
6
18
#DDW2024 researcher @dr_aac found that a machine-learning genetic algorithm — the “hungry gut” phenotype test — can predict which patients will do best on semaglutide weight-loss drugs @AmerGastroAssn
0
10
58
Family in more ways than one #DDW2024 @AdamBledsoeMD @loftinator @DrJohnKisiel @VictorChedidMD @amjohnsonMD @GuiRamosMD @soloftus @bethbloop @TharayilVivek
0
3
17